Should I buy RenaissanceRe (RNR) stock or is it too late?

RenaissanceRe · Financials · price $330
Logo RenaissanceReSee the full RenaissanceRe (RNR) profile
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Mizuho82% of its targets hit on this sector (28 calls tested). It aims for $329 (-0.4 %), call made on July 10, 2026, maturing on July 10, 2027 (49 d ago).

The 9 reliable analysts $341+3.2 %
The 3 other firms $354+7.1 %
How to read it: the 9 reliable firms are not filtered by optimism — 5 aim above the price, 4 below, hence their $341 median. “The 3 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on RenaissanceRe

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.
Firm% rightGain vs sectorCallsAims for
Citigroup83 %+19.1 %18$345 +4%
Keefe, Bruyette & Woods100 %+16.2 %8$350 +6%
Wells Fargo78 %+11.4 %18$329 +0%
B of A Securities57 %+3.7 %7$438 +33%
Barclays56 %-2.2 %9$341 +3%
Evercore ISI Group20 %-10.9 %5$330 +0%
Deutsche Bank29 %-1.5 %7
In short — Should you invest in RenaissanceRe? Is it too late, still worth it? Analysts are split (25% buy, median target $343, i.e. +4%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

  • Few solid positives from analysts right now: of 12 ratings, only 3 buys, and the median price target ($343) is barely above the price (+4%, at $330). Caution prevails.

⚠️ Reasons to hesitate

  • Even the most reliable firm on RNR, Morgan Stanley (100% hit rate, 3 scored calls), only targets $320 (call made on July 6, 2026, maturing on July 6, 2027) (-3%) in its most recent call, and $290 (call made on November 17, 2025, maturing on November 17, 2026) (-12%) in the one coming due soonest. The stock may already have run past its target.
  • The consensus is not unanimous: of 12 ratings, 9 are neutral.
  • Limited upside: the median target is only +4% from the current price.
  • A 12-month target is not a guaranteed path: the price can fall in the meantime.
  • Negligible dividend (0.4% yield): your return depends mostly on price appreciation.

The analyst consensus on RNR

Median target $343 (+4%) · 12 ratings · Hold consensus

Strong Buy00%
Buy325%
Hold975%
Sell00%
Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in RenaissanceRe now?

We won't decide for you. The facts: 25% of analysts rate it a buy, median target $343 (+4%), and Morgan Stanley (most reliable on RNR, 100%) targets $320. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in RenaissanceRe?

Not according to analysts: the median target ($343) is still +4% above the current price ($330) (most reliable on RNR: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is RenaissanceRe still worth investing in?

It depends on the gap between the price ($330) and its estimated value: analysts target $343 on median (+4%), with 25% buys (most reliable on RNR: Morgan Stanley, 100%). Cross-check with their real reliability on RNR and the cautions above. Information, not advice.

What's the main risk in buying RNR?

Even the most reliable firm on RNR, Morgan Stanley (100% hit rate, 3 scored calls), only targets $320 (call made on July 6, 2026, maturing on July 6, 2027) (-3%) in its most recent call, and $290 (call made on November 17, 2025, maturing on November 17, 2026) (-12%) in the one coming due soonest. The stock may already have run past its target.

→ Go deeper: the full RenaissanceRe profile (consensus, analyst reliability, price target, performance).

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)